Clinical Trial on the Usefulness of an Intensive Low-Density Lipoprotein Cholesterol Treatment and Familial Hypercholesterolemia Screening Clinical Pathway for Acute Coronary Syndrome: The Hokuriku-plus Acute Coronary Syndrome Registry Study - Rationale and Study Design.

Save

Background

Acute coronary syndrome (ACS) is the critical situation caused by decreased blood flow of the coronary arteries. The most recent clinical guideline compiled by the Japanese Circulation Society (JCS) recommends lowering low-density lipoprotein cholesterol (LDL-C) to <70 mg/dL in patients with ACS, because of the lack of clinical evidence. It has been shown that there are substantial numbers of patients with familial hypercholesterolemia (FH) among ACS patients.

On this basis, we intend assembling a multicenter registry to establish the evidence for lowering LDL-C <55 mg/dL while also clarifying the proportion of FH patients among Japanese ACS patients using a prespecified clinical pathway.

Methods and Results

The Hokuriku-plus ACS registry is a prospective, observational, multicenter cohort study, enrolling consecutive ACS patients from 14 participating hospitals in Hokuriku region of Japan from October 2025 to September 2027. A total of 1,000 patients will be enrolled followed over 1 year. The primary endpoint is the proportion of patients who attain LDL-C <55 mg/dL at 4 weeks.

This study has been registered at the Japan Registry of Clinical Trials (jRCT1040250123).

Conclusions

We will disseminate the final results at international conferences and in a peer-reviewed journal.

Acute coronary syndrome (ACS) is a critical situation, as well as an important cause of death worldwide. Coronary revascularization, as well as management of complications, in coronary care unit has been improving over the years, leading to better short-term prognosis of ACS patients.1,2 However, the recurrence rate of ACS is still inadequate during long-term follow-up.3,4 We know that low-density lipoprotein cholesterol (LDL-C) plays a central role in coronary atherosclerosis, and that LDL-cholesterol lowering therapies could lead to less recurrence of ACS events.refs Based on this, clinical guidelines stipulate LDL-C treatment targets for this special situation. For example, the European Society of Cardiology and European Atherosclerosis Society compiled a guideline recommending LDL-C <55 mg/dL according to clinical evidence from patients with ACS.5 However, the most recent clinical guideline compiled by the Japanese Circulation Society (JCS) set the goal at <70 mg/dL due to the lack of clinical evidence from Japanese patient populations.6 No prior study has fulfilled this gap, and more importantly, the attainment rate of this goal is approximately 30% in Japan.7 Therefore, developing a clinical pathway clarifying how to lower LDL-C to achieve the treatment target has attracted a lot of attention.8 In addition, recent studies have suggested that 5–15% of the ACS patients have familial hypercholesterolemia (FH),9–11 which has an important implication for relatives because this is an autosomal dominant disorder.

Against this background, in this study we will assemble a multicenter registry that aims to establish evidence for lowering LDL-C to <55 mg/dL while also clarifying the proportion of FH patients among Japanese ACS patients using a prespecified clinical pathway.

Methods

Overall Study Design

Recruitment for this prospective, non-randomized, multicenter single-arm interventional cohort study extends from October 2025 to September 2027. We will enroll consecutive ACS patients from 14 participating hospitals located in the Hokuriku region (Figure 1). The proposed time frame for data collection after the initial enrollment is shown in Supplementary Table 1.

Details are described in the Supplementary Material. The study complies with the Declaration of Helsinki, the Ethical Guidelines for Medical and Health Research Involving Human Subjects, and all other applicable laws and guidelines in Japan. In addition, this study protocol (ver.

1.1) has been approved by the Institutional Review Board (IRB) at Kanazawa University (No. 2025-002) and registered at the Japan Registry of Clinical Trials Registry (jRCT1040250123). Figure 1.Participating study centers, including 14 hospitals across the Hokuriku region of Japan.

Blue circles indicate location of participating hospitals. Thirty-one of the 14 hospitals are located in the Hokuriku region of Japan.

Study Participants

Patients fulfilling all inclusion criteria and who can be followed for 52 weeks (Supplementary Table 2) will be enrolled, and those with either of the exclusion criteria will be excluded (Supplementary Table 3). Patients are asked to give written informed consent using forms that have been approved by the IRB at Kanazawa University. Trial participants are required to understand the content of the consent form before giving their acceptance, and the forms must be dated and signed by both trial participants and investigators.

Intervention

There are 2 major interventions in this study. First, LDL-cholesterol lowering therapy will be introduced according to conditions at presentation (Figure 2). In brief, patients will be divided into 3 groups (those who are or are not under high-intensity statin therapy, or those with statin-intolerance).

LDL-cholesterol lowering medications, including high-intensity statins, ezetimibe, and PCSK9 inhibitors will be introduced to achieve LDL-C <55 mg/dL. Second, all ACS patients will be tested for FH (Figure 3), including genetic testing if needed. Figure 2.Proposed clinical pathway of intervention for low-density lipoprotein cholesterol (LDL-C) in patients with acute coronary syndrome.Figure 3.Proposed clinical pathway for diagnosis of familial hypercholesterolemia (FH) in patients with acute coronary syndrome (ACS).

CAD, coronary artery disease; LDL, low-density lipoprotein.

Patient and Public Involvement

This research is being carried out without patient involvement. Patients are not able to comment on the study design nor are they consulted on developing patient-relevant outcomes or interpreting the results. Patients are not contributing to the writing or editing of this document for readability or accuracy.

Genetic Testing

If needed, we will sequence the exons of 4 FH-related genes (LDLR, PCSK9, APOB, and LDLRAP1) as well as other genes associated with Mendelian lipid disorders, such as ATP-binding cassette subfamily G member 5 (ABCG5) and ATP-binding cassette subfamily G member 8 (ABCG8) using the Illumina MiSeq system. The variant is defined as causal when it fulfills 1 of the following criteria: (a) it is registered as pathogenic/likely pathogenic in the ClinVar database; (b) minor allele frequency is <1% in the East Asian population with (i) protein-truncating variants (nonsense, canonical splice sites, or frameshift) and (ii) missense variants in the LDLR gene that 5 in silico damaging scores (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, MutationTaster2, LRT) all predicted as pathogenic; or (c) missense variants reported as pathogenic in the Japanese population (PCSK9 p.Val4Ile and p.Glu32Lys); and (d) eXome-Hidden Markov Model (XHMM) software predicted as copy number variations in the LDLR gene (large duplication/large deletion). Details are described elsewhere.12

Data Collection

Attending physicians and research assistants will collect data under the supervision of the clinicians responsible for this study at each participating hospital. The primary source of information will be the electronic health records at each institute. Data are recorded through electronic data capture (EDC) using the browser-based, metadata-driven EDC software REDCap.

The details and statistical analyses are illustrated in the Supplementary Material.

Outcomes

The primary endpoint of this study is the proportion of patients who attain LDL-C <55 mg/dL at 4 weeks. The secondary endpoints are: the proportions of patients who attain LDL-C <55 mg/dL at 12 and 52 weeks, the proportions of patients who attain LDL-C <70 mg/dL at 4, 12 and 52 weeks, the proportion of FH patients at 52 weeks, the number of ASCVD events, and the occurrence of any side-effects.

Discussion

The Hokuriku-plus ACS registry is a prospective, non-randomized, multicenter single-arm interventional cohort study designed to elucidate the efficacy and safety of implementing a clinical pathway targeting a LDL-C level <55 mg/dL among Japanese ACS patients. In addition, we intend to clarify the role of FH among ACS patients. The registry includes all patients admitted to participating centers with ACS, avoiding selection bias to elucidate a more complete picture of the clinical characteristics, medications, and outcomes of patients with ACS.

LDL-C is the major cause of coronary atherosclerosis, and thus a reduction in the level of LDL-C is associated with reduced recurrence of ACS.13,14 The JCS guideline stipulates a LDL-C treatment target <70 mg/dL among patients with ACS, but we consider further lowering of the LDL-C in Japanese patients would be recommended with sufficient clinical evidence. The aim of our study is to provide that evidence. In addition, the prevalence of FH among ACS patients is reportedly 5%,15 and in our prospective multicenter observational study (EXPLORE-J) we found that approximately 6% of ACS patients had FH clinically.11 However, we could not implement genetic testing for FH in that study, so the true rate could still have been underestimated.

In this regard, comprehensive genetic testing for all patients who need it is a strength of the Hokuriku-plus ACS registry. It will not only enable us to confirm the diagnosis of FH and future ASCVD risk, but will also facilitate decision-making during treatment and promote cascade screening among the identified patients’ relatives. In addition, study data will help improve the present FH clinical diagnostic criteria in Japan and potentially worldwide.

The genetic analyses will be performed as a part of the research and the results will be returned to the patients, with genetic counseling available upon request.

Study Limitation

The study is only being conducted in the Hokuriku district of Japan, and thus the results obtained may not represent the whole Japanese population.

Study Strengths

• This will be the first prospective multicenter cohort study in Japan to assess the efficacy of a clinical pathway to lower LDL-C <55 mg/dL in ACS patients.

• Clarifying the proportion of FH cases among ACS patients using genetic testing to confirm the diagnosis of FH and future ASCVD risk, and facilitate decision-making over treatment as well as promoting cascade screening of relatives.

• Study data will help improve the current clinical diagnostic criteria of FH in Japan, and potentially worldwide.

In conclusion, we will demonstrate the study design and protocol of the Hokuriku-plus ACS registry. We hypothesize that the proposed clinical pathway will help us further reduce LDL-C levels safely among ACS patients, and that >50% of the patients will attain the LDL-C treatment target <55 mg/dL. We also expect to see a proportion of ACS patients with FH in their clinical background.

Finally, this study will provide insights into the importance of intensive LDL-cholesterol lowering therapy for patients with extremely high cardiovascular risk.

Competing Interests Statement

Hayato Tada received a research grant from Amgen K.K.

Role of the Sponsor

This funding source has no role in the design of this study and will not have any role during its execution, analysis, interpretation of the data, or decision to submit results.

Author Contributions

All of the authors designed and are conducting the study. All authors performed a critical review and approved the final version of this manuscript.

IRB Information

The present study was approved by the IRB at Kanazawa University (No. 2025-002).

Supplementary Files

Related articles

PubMed

Using Implementation Science to Improve Guidelines-Based Care to Lower Atherosclerosis Risk Due to Familial Hypercholesterolemia.

Purpose of the Review Implementation science, a multi-method research area that integrates input from constituents and content experts, has emerged as an important tool in improving implementation of evidence-based practices. This review summarizes three ongoing implementation studies focused on identification of patients with significantly increased risk for atherosclerotic cardiovascular disease (ASCVD) due to genomic risk such as familial hypercholesterolemia (FH) within a single health syst...

PubMed

Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis.

Background Many patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets with statin monotherapy, calling for a combination of statins and ezetimibe. This systematic review and network meta-analysis evaluated the comparative effectiveness and safety of atorvastatin monotherapy, atorvastatin/ezetimibe free-equivalent combination (AS/EZ FEC), and fixed-dose combination (AS/EZ FDC) in patients with hypercholesterolemia. Methods Randomized controlled trials were retrieved from...